Vancouver company launches new superbug test

Kent, Heather
September 1999
CMAJ: Canadian Medical Association Journal;9/21/99, Vol. 161 Issue 6, p679
Academic Journal
Reports about a test for detecting methicillin-resistant Staphylococcus aureus (MRSA) from the Canadian company I.D. Biomedical Corporation. Test approval by the United States Food and Drug Administration and expected approval by Health Canada; Comments by the Dr. Tony Holler, the company's president, about the speed and accuracy of the test; Preparation of I.D. Biomedical for a test to detect vancomycin-resistant enterococci bacteria.


Related Articles

  • A superbug becomes even more frightening.  // RN;Dec97, Vol. 60 Issue 12, p16 

    Reports that Staph infection has become resistant to the drug vancomycin. Reference to a case in Japan involving a 4-month-old boy with a surgical site infection who developed methicillin-resistant Staphylococcus aureus and was given vancomycin.

  • Vancomycin Dosing Practices, Trough Concentrations, and Predicted Area Under the Curve in Children With Suspected Invasive Staphylococcal Infections. Chhim, Rebecca F.; Arnold, Sandra R.; Lee, Kelley R. // Journal of the Pediatric Infectious Diseases Society;Sep2013, Vol. 2 Issue 3, p292 

    A response from the authors of the article "Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections" in the 2013 issue is presented.

  • VRSA transmission not a current threat. Cintolo, Rebekah // Infectious Disease News;Mar2008, Vol. 21 Issue 3, p38 

    The article discusses research being done on vancomycin-resistant Staphylococcus aureus (VRSA). It references a study by Dawn M. Sievert and colleagues that was published in a 2008 issue of the journal "Clinical Infectious Diseases." The immediate diagnosis of vanA-positive VRSA by microbiology...

  • Canadian company to develop mock pandemic vaccine. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;3/1/2005, Vol. 172 Issue 5, p623 

    Focuses on a mock pandemic vaccine being developed by Vancouver-based ID Biomedical Corp. to protect people against H5N1 influenza in British Columbia. Utilization of reverse genetics technology; Requirements for the phase II clinical trials; Comment from Michele Roy, spokesperson for ID...

  • Antibiotics.  // Cardiovascular Pharmacology Manual;2008, p62 

    The article presents information about several antibiotics, they include cephalexin, ampicillin and vancomycin. Some of the diseases treated by these antibiotics are life threatening infections and staphylococcal infections. Their adverse effects include ototoxicity, nephrotoxicity, anaphylaxis...

  • In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci. El-Azizi, Mohamed; Rao, Suma; Kanchanapoom, Termkiat; Khardori, Nancy // Annals of Clinical Microbiology & Antimicrobials;2005, Vol. 4, p2 

    Shed cells or disrupted parts of the biofilm may enter the circulation causing serious and very hard to treat biofilm-associated infections. The activity of antimicrobial agents against the shed cells/ disrupted biofilms is largely unknown. Methods: We studied the in vitro susceptibility of...

  • vancomycin.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1185 

    The article provides information on vancomycin, an anti-infective agent. The drug treats staphylococcus infections including endocarditis and meningitis. Moreover, pharmacokinetics, adverse events and drug interactions are mentioned. It addresses the dosage forms of the drug. It also offers...

  • BSAC standardized disc susceptibility testing method (version 10). Andrews, J. M.; Howe, R. A. // Journal of Antimicrobial Chemotherapy (JAC);Dec2011, Vol. 66 Issue 12, p2726 

    The BSAC standardized disc susceptibility testing method remains unchanged, but there are considerable changes to the interpretative criteria due to continuing harmonization with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC breakpoints. There are a number of agents...

  • ANTIMICROBIAL RESISTANCE: GUIDELINES FOR THE PRACTICING ORTHOPAEDIC SURGEON. Osmon, Douglas R. // Journal of Bone & Joint Surgery, American Volume;Dec2001, Vol. 83-A Issue 12, p1891 

    Discusses guidelines that practicing orthopedic surgeon should consider in managing multidrug resistant pathogens. Scope and mechanisms of antimicrobial resistance; Vancomycin-resistant enterococci; Staphylococci; Solutions to bacterial resistance.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics